>>> Part 3 of 3...
II) Washington, DC: Galen Fress, 1989.
9. Alliance for Cannabis Therapeutics: No accepted medical
value?? ACT News. Spring, 1995;4.
10. Grinspoon L, Bakalar JB: Marihuana as medicine: a plea
for reconsideration. JAMA. 1995;273 (23): 1875-1876.
11. Government extinguishes marijuana access, advocates
smell politics. JAMA. May 20, 1992;267(19):2673-2674.
12. Colasanti BK: Review: Ocular hypotensive effect of
marihuana cannabinoids: correlate of central action or
separate phenomenon. J Ocular Pharmacol.
1986;2(3):295-304.
13. Hepler RS, Frank IM: Marihuana smoking and intraocular
pressure. JAMA. 1971;217; 1392.
14. Sallan SE, Zinberg WE, Frei III E: Antiemetic effect of
delta-9-tetrahydrocannabinol in patients receiving cancer
chemotherapy. New Engl J Med, 1975;293(16):795-797
15. Sallan SE. Cronin C, Zelen M, Zinberg NE: Antiemetics
in patients receiving chemotherapy for cancer. New Engl
J Med 1980;302: 135-138,
16. Vinciguerra V, Moore T. Brennan, E: Inhalation marijuana
as an antiemetic for cancer chemotherapy. NY State J Med.
1988;88:525-527.
17. Nelson K, Walsh D, Deeter P. et al: A phase II study of
delta-4-tetrahydrocannabinol for appetite stimulation in
cancer-associated anorexia. J Palliative Care.
1994; 10(1); 14-18.
18. Regelson W, Butler JR, Schultz J et al: Delta-9-THC as an
effective antidepressant and appetite stimulating agent in
advanced cancer patients. In Int Conf Pharmacol Connabis,
Ed S Szara, MC Braude. Savannah: Raven, 1975.
19. Foltin RW, Fischman MW, Byrne MF: Effects of smoked
marijuana on food intake and body weight of humans
living in a residential laboratory. Appetite. 1988;11:1-14.
20. Clifford DB: Tetrahydrocannabinol for tremor in multiple
sclerosis. Ann Neurol. 1983;13:669-671.
21. Malec J, Harvey RF, Cayner JJ: Cannabis effect on
spasticity in spinal cord injury. Arch Phys Med Rehab.
1982;35:198.
22. MeinckH, Schonle PW, Conrad B: Effect of cannabinoids
on spasticity and ataxia in multiple sclerosis. J Neurol.
1989;236:120-122,
23. Petro D: Marihuana as a therapeutic agent for muscle
spasm or spasticity. Psychosomatics. 1980;21:81-85.
24. Petro D, Ellenberger C: Treatment of human spasticity
with delta-9-tetrahydrocannabino. J Clin Pharmacol.
1981;21:413S-416S.
25. Ungerleider JT, Andyrsiak T, Fairbanks L, et al: Delta-9-
THC in the treatment of spasticity associated with multiple
sclerosis.
26. Johnson MR, Melvin LS, Althius, TH et al: Selective and
potent analgesics derived from cannabinoids. J Clin
Pharmacol, 198;21:217S-282S.
27. Maurer M, Henn V, Ditrrich A, et al: Delta-9-
tetrahydrocannabinol shows antispastic and analgesic
effects in a single case double-blind trial. Eur Arch
Psychiatry Clin Neurosci. 1990:240:1-4,
28. Noyes Jr. R, Brunk SF, Avery DH, et al: The analgesic
properties of delta-9-tetrahydrocannabinol and codeine.
Clin Pharmocol Ther; 1975;18(1):84-89.
29. Cunha JM, Carlini EA, Pereira AE, et al: Chronic
administration of cannabidiol to healthy volunteers and
epileptic patients. Pharmacology. 1980;21:175-185.
30. Feeney D: Marihuana use among epileptics. JAMA.
1976;235:1105.
31. Karler R, Turkanis SA: The cannabinoids as potential
antiepileptics. J Clin Phrarmacol. 1981;21:437S-448S.
32. Institute of Medicine: Marijuana and Health. Washington,
DC: National Academy Press, 1982.
33. Mechoulam R, Ed: Cannabinoids as Therapeutic Agents.
Boca Raton, FL: CRC Press, 1986.
34. Cannabis clubs open for medicinal business. USA Today,
October 1, 1993:B1, B5.
35. BergerJ: Mother's homemade marijuana: a plan to aid her
son leads to arrest and push for change. The New York
Times, October ll, 1993.
36. American Public Health Association Resolution No. 7014:
Marijuana and the Law. APHA Public Policy Statements,
1948-present, cumulative. Washington, DC: APHA, current volume.
===End===
___
X Blue Wave/DOS v2.30 X
--- Maximus 3.01
---------------
* Origin: Who's Askin'? (1:17/75)
|